Item request has been placed!

Item request cannot be made.

Processing Request

نتائج البحث

Display Settings

النتائج لكل صفحة: 10

Sort By: Relevance

فلترة النتائج

فلترة بواسطة : مؤلف Subject : pyrazinamide

إعادة تعيين خيارات الفبترة

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.

Authors : Lee M; Clinical Research Section, International Tuberculosis Research Center, 247, Jangchungdan-ro, Jung-gu, Seoul, 04564, Republic of Korea.; Mok J

Subjects: Drug Resistance, Multiple, Bacterial*; Antitubercular Agents/Antitubercular Agents/Antitubercular Agents/*administration & dosage ; Levofloxacin/Levofloxacin/Levofloxacin/*administration & dosage

Source: Trials [Trials] 2019 Jan 16; Vol. 20 (1), pp. 57. Date of Electronic Publication: 2019 Jan 16.Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea

Authors : Mok, Jeongha^1,2 (AUTHOR); Lee, Myungsun^1,3 (AUTHOR); Kim, Deog Kyeom^4,5 (AUTHOR)

Subjects: *MULTIDRUG-resistant tuberculosis; *LINEZOLID; *PYRAZINAMIDESOUTH Korea

Source: Lancet. 10/30/2022, Vol. 400 Issue 10362, p1522-1530. 9p.

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي